Skip to main content
The Globe and Mail
Support Quality Journalism
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); }

Lower-than-expected third-quarter revenues and a surprise net loss from Organigram early Monday failed to dent investor confidence in the licenced cannabis producer.

Shares of the New Brunswick-based LP closed 4.2 per cent higher Monday on the Toronto Stock Exchange. In New York, Organigram’s Nasdaq-listed shares briefly fell as much as 11 per cent in pre-market trading before rapidly recovering to close up 4.6 per cent.

Cannabis stocks were broadly higher Monday after the sector suffered widespread losses last week. However, Organigram also outperformed the Horizons Marijuana Life Sciences Index, an exchange-traded fund (ETF) that seeks to replicate the performance of the North American cannabis industry overall, which gained 1.6 per cent on Monday.

Story continues below advertisement

The company joins other major growers such as Canopy Growth, Cronos Group and Supreme Cannabis in falling below market expectations in their latest financial reports. Unlike the market reaction to results from its peers, however, Organigram investors and analysts seem willing to accept the company’s explanation: lower crop yields in Q3 were “an anomaly” caused by a failed cultivation experiment and the finessing process involved with growing new strains.

According to the company’s management discussion and analysis (MD&A) document, the experiment revolved around harvesting clones (clippings from larger cannabis plants used for replanting) from “later stage” mother plants.

“While initial sample results using this technique increased cost efficiency, the yields were significantly lower than historical results when the process was rolled out on a broader basis,” an excerpt from page 15 of the MD&A explained, adding Organigram “reverted to its proven methodology of creating clones and during Q4 of Fiscal 2019 actual yields have returned to previous levels.”

“During this period, the Company also trialed a number of new strains,” the MD&A said. “The optimization process with these new strains impacted a number of production rooms with lower than projected harvest results as well. The Company believes it has now optimized the conditions for these new strains and has consistently seen production levels return to management’s targeted yields.”

Organigram now believes it “has identified what it views as an optimal balance of high yields and high cannabinoid content,” the document said.

Revenue of less than $25-million for the three-month period was below average analyst expectations of $30-million, though the figure still represented dramatic growth from the $3.4-million in revenue Organigram generated during the same time last year. The net loss of $0.07 per share compared to a net profit of $0.02 per share in Q3 of 2018 and analyst expectations of three cents in per-share profits for its latest quarter.

Eight Capital analyst Graeme Kreindler dismissed the results as “an isolated event” in a midday Monday note to clients. Douglas Miehm of RBC Securities was more critical, telling clients “this quarter’s results reaffirm our view that OGI could face difficulties in delivering strong [revenue] and margin growth over the next quarter or two.”

Story continues below advertisement

Despite those near-term concerns, Mr. Miehn nonetheless commended Organigram as being “one of the best-managed LPs in Canada,” adding he “would become more positive on the shares if margins bounce considerably.” Gross Margins shrank to 50 per cent in Organigram’s third quarter, compared to 60 per cent in the previous quarter and analyst expectations for margins to remain largely the same.

Margins should bounce back along with crop yields in Q4, the company said

Paradigm Capital managing director Corey Hammill was similarly unfazed in his own Monday note to clients.

“The market never likes a miss,” he said, “[but] we continue to believe that in the evolving cannabis industry, Organigram has the right combination of size, scope and scale to be a long-term winner.”

can-pro-graphic

The Globe and Mail

Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies